Anti-CGRP/anti-IL-23 bispecific antibodies and uses thereof
US10577415B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 26, 2018 |
| Grant date | Mar 3, 2020 |
| Priority date | — |
| Expiry date | May 3, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease (CD) and Ulcerative Colitis (UC), and other autoimmune diseases such as psoriatic Arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AtD). The bispecific antibodies of the invention are useful for treating pain associated with the aforementioned diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.